Nifedipine: Can this calcium channel blocker be used “off label” to inhibit the development and symptoms of Alzheimer’s disease and related beta-amyloid-producing syndromes

Alzheimer’s disease needs no formal introduction. Losing a lifetime of information, experience, and memories is an undesirable and daunting end to a person’s life, affecting not only the person but also their family and friends. The cost to the individuals involved and society as a whole is onerous. Currently, no medications or successful treatment are available to stop the progression of this disease; there are only ways to prolong life and put off the inevitable neural degeneration and cognitive dysfunction. The genetic component of Alzheimer’s is at the research forefront, and the relationship between the pathways of similar amyloid-related genetic conditions, such as Down syndrome, may have a commonality. It is considering these pathways where “off label” use of a common medication, Nifedipine, may offer improved outcomes in the treatment or amelioration of Alzheimer’s-related symptoms in halting the progression of this most pernicious and dreadful disease.